全程局部同步推量适形放射治疗在不可手术的中心型非小细胞肺癌中的应用
DOI: 10.3971/j.issn.1000-8578.2015.02.018
Keywords: A Meta-analysis,NSCLC的疫苗治疗研究进展,Effect of Vascular Endothelial Cadherin on Invasion and Metastasis of Non-small Cell Lung Cancer Cells and Related Mechanism,Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Prognosis of Clinical Stage ⅢA(N2) Non-small Cell Lung Cancer Patients Received Radiotherapy,Effect of Intensity Modulated Radiotherapy Combined with Hormonal Therapy on Fatigue in Patients with Locally Advanced Prostate Cancer,Quality Assessment of Reports of Randomized Controlled Trials Published in Chinese in Field of Non-small Cell Lung Cancer in China,Efficacy and Safety of Weekly Liposome-paclitaxel or Oxaliplatin Combined with Tegafur on Elderly Advanced Gastric Cancer,Review of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adjuvant Treatment of Non-small Cell Lung Cancer,Evaluation of Ligand-targeted PCR Method in Detecting Tumor Cell Levels in Pleural Effusion of Patients with Non-small Cell Lung Cancer,Association of Cytochrome P450 2E1-1239G>C Genetic Variation with Prognosis of Metastatic Non-small Cell Lung Cancer Patients
Abstract:
摘要 目的 观察不可手术的中心型非小细胞肺癌患者应用全程局部同步推量适形放射治疗的不良反应及临床疗效。方法 收集2007年12月至2013年7月在河北医科大学第四医院收治的不可手术的中心型非小细胞肺癌患者44例，均经组织学或细胞学证实，采用SIB-CR技术制定放疗计划，PTV处方剂量5 040 cGy/28次（180 cGy/次），肿瘤局部处方剂量6 440 cGy/28次（单次分割230 cGy/次），1次/日，5次/周, 全程放疗时间5.5周。观察不良反应及临床疗效。结果 放疗结束疗效显示：总有效率为97.70%（43/44）。全组病例1、2、3、5年生存率分别为70.9%、44.8%、31.0%、18.6%。1、2、3、5年局部控制率分别为93.8%、63.9%、58.1%、58.1%。急性放射性肺炎和放射性食管炎的发生率分别为29.6%和25%。骨髓抑制发生率为43.2%（19/44）。结论 全程局部同步推量适形放射治疗不可手术的中心型非小细胞肺癌，临床有效率高，患者耐受性好。长期生存和晚期并发症有待于进一步观察
Full-Text
